Research Article
[Retracted] Overexpressed RING Finger 44 Correlates with Poor Prognosis in Hepatocellular Carcinoma
Table 1
Baseline characteristics of the RNF44 high-expression set and the low-expression set in the TCGA cohort.
| | Characteristic | Low expression of RNF44 | High expression of RNF44 |
| | Total | 187 | 187 | | T Stage | | | | T1 | 100 (27%) | 83 (22.4%) | | T2 | 46 (12.4%) | 49 (13.2%) | | T3 | 33 (8.9%) | 47 (12.7%) | | T4 | 5 (1.3%) | 8 (2.2%) | | N stage | | | | N0 | 126 (48.8%) | 128 (49.6%) | | N1 | 1 (0.4%) | 3 (1.2%) | | M stage | | | | M0 | 135 (49.6%) | 133 (48.9%) | | M1 | 2 (0.7%) | 2 (0.7%) | | Pathologic stage | | | | Stage I | 96 (27.4%) | 77 (22%) | | Stage II | 45 (12.9%) | 42 (12%) | | Stage III | 33 (9.4%) | 52 (14.9%) | | Stage IV | 3 (0.9%) | 2 (0.6%) | | Tumor status | | | | Tumor free | 108 (30.4%) | 94 (26.5%) | | With tumor | 71 (20%) | 82 (23.1%) | | Gender | | | | Female | 55 (14.7%) | 66 (17.6%) | | Male | 132 (35.3%) | 121 (32.4%) | | Race | | | | Asian | 74 (20.4%) | 86 (23.8%) | | Black or African American | 7 (1.9%) | 10 (2.8%) | | White | 98 (27.1%) | 87 (24%) | | Age | | | | ≤60 | 78 (20.9%) | 99 (26.5%) | | >60 | 109 (29.2%) | 87 (23.3%) | | Weight (kg) | | | | ≤70 | 84 (24.3%) | 100 (28.9%) | | >70 | 92 (26.6%) | 70 (20.2%) | | Height (cm) | | | | <170 | 96 (28.2%) | 105 (30.8%) | | ≥170 | 76 (22.3%) | 64 (18.8%) | | BMI | | | | ≤25 | 83 (24.6%) | 94 (27.9%) | | >25 | 88 (26.1%) | 72 (21.4%) | | Residual tumor | | | | R0 | 165 (47.8%) | 162 (47%) | | R1 | 6 (1.7%) | 11 (3.2%) | | R2 | 1 (0.3%) | 0 (0%) | | Histologic grade | | | | G1 | 37 (10%) | 18 (4.9%) | | G2 | 94 (25.5%) | 84 (22.8%) | | G3 | 49 (13.3%) | 75 (20.3%) | | G4 | 5 (1.4%) | 7 (1.9%) | | Adjacent hepatic tissue inflammation | | | | None | 66 (27.8%) | 52 (21.9%) | | Mild | 51 (21.5%) | 50 (21.1%) | | Severe | 8 (3.4%) | 10 (4.2%) | | AFP (ng/ml) | | | | ≤400 | 123 (43.9%) | 92 (32.9%) | | >400 | 23 (8.2%) | 42 (15%) | | Albumin (g/dl) | | | | <3.5 | 37 (12.3%) | 32 (10.7%) | | ≥3.5 | 119 (39.7%) | 112 (37.3%) | | Prothrombin time (s) | | | | ≤4 | 105 (35.4%) | 103 (34.7%) | | >4 | 48 (16.2%) | 41 (13.8%) | | Child–Pugh grade | | | | A | 120 (49.8%) | 99 (41.1%) | | B | 12 (5%) | 9 (3.7%) | | C | 0 (0%) | 1 (0.4%) | | Vascular invasion | | | | No | 108 (34%) | 100 (31.4%) | | Yes | 56 (17.6%) | 54 (17%) | | OS event | | | | Alive | 129 (34.5%) | 115 (30.7%) | | Dead | 58 (15.5%) | 72 (19.3%) | | DSS event | | | | Alive | 145 (39.6%) | 142 (38.8%) | | Dead | 38 (10.4%) | 41 (11.2%) | | PFI event | | | | Alive | 102 (27.3%) | 89 (23.8%) | | Dead | 85 (22.7%) | 98 (26.2%) |
|
|
RNF44: ring finger protein 44; AJCC7: American Joint Committee on Cancer 7th edition.
|
